What's Happening?
Zepto Life Technology has announced that its FungiFlex Mold Panel, a liquid biopsy test, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This test is designed to aid in diagnosing invasive mold infections
by detecting fungal cell-free DNA directly from plasma. The FungiFlex Mold Panel is available for physician ordering through Zepto Life Technology's CLIA-certified laboratory as a Laboratory Developed Test (LDT). Invasive mold infections are particularly challenging to diagnose and are associated with high morbidity and mortality in immunocompromised patients. The test aims to provide organism-level identification of clinically relevant mold pathogens, addressing significant limitations of current diagnostic approaches.
Why It's Important?
The FDA's Breakthrough Device Designation is significant as it highlights the potential of the FungiFlex Mold Panel to address a critical unmet need in diagnosing invasive mold infections. These infections are difficult to diagnose and can be life-threatening, especially for immunocompromised individuals. The ability to identify specific pathogens quickly and accurately can lead to more effective treatment decisions and improved patient outcomes. This designation also underscores the importance of innovative diagnostic tools in enhancing healthcare delivery and patient care, particularly in complex and challenging medical conditions.
